دورية أكاديمية
Final analysis of survival outcomes in the phase 3 FIRST trial of up-front treatment for multiple myeloma
| العنوان: | Final analysis of survival outcomes in the phase 3 FIRST trial of up-front treatment for multiple myeloma |
|---|---|
| المؤلفون: | Facon, Thierry, Dimopoulos, Meletios A, Dispenzieri, Angela, Catalano, John V, Belch, Andrew, Cavo, Michele, Pinto, Antonello, Weisel, Katja, Ludwig, Heinz, Bahlis, Nizar J, Banos, Anne, Tiab, Mourad, Delforge, Michel, Cavenagh, Jamie D, Geraldes, Catarina, Lee, Je-Jung, Chen, Christine, Oriol, Albert, De La Rubia, Javier, White, Darell, Binder, Daniel, Lu, Jin, Anderson, Kenneth C, Moreau, Philippe, Attal, Michel, Perrot, Aurore, Arnulf, Bertrand, Qiu, Lugui, Roussel, Murielle, Boyle, Eileen, Manier, Salomon, Mohty, Mohamad, Avet-Loiseau, Herve, Leleu, Xavier, Ervin-Haynes, Annette, Chen, Guang, Houck, Vanessa, Benboubker, Lotfi, Hulin, Cyrille |
| المساهمون: | Facon, Thierry, Dimopoulos, Meletios A, Dispenzieri, Angela, Catalano, John V, Belch, Andrew, Cavo, Michele, Pinto, Antonello, Weisel, Katja, Ludwig, Heinz, Bahlis, Nizar J, Banos, Anne, Tiab, Mourad, Delforge, Michel, Cavenagh, Jamie D, Geraldes, Catarina, Lee, Je-Jung, Chen, Christine, Oriol, Albert, De La Rubia, Javier, White, Darell, Binder, Daniel, Jin, Lu, Anderson, Kenneth C, Moreau, Philippe, Attal, Michel, Perrot, Aurore, Arnulf, Bertrand, Qiu, Lugui, Roussel, Murielle, Boyle, Eileen, Manier, Salomon, Mohty, Mohamad, Avet-Loiseau, Herve, Leleu, Xavier, Ervin-Haynes, Annette, Chen, Guang, Houck, Vanessa, Benboubker, Lotfi, Hulin, Cyrille |
| سنة النشر: | 2018 |
| المجموعة: | IRIS Università degli Studi di Bologna (CRIS - Current Research Information System) |
| مصطلحات موضوعية: | newly diagnosed multiple myeloma |
| الوصف: | This FIRST trial final analysis examined survival outcomes in patients with transplant-ineligible newly diagnosed multiple myeloma (NDMM) treated with lenalidomide and low-dose dexamethasone until disease progression (Rd continuous), Rd for 72 weeks (18 cycles; Rd18), or melphalan, prednisone, and thalidomide (MPT; 72 weeks). The primary endpoint was progression-free survival (PFS; primary comparison: Rd continuous vs MPT). Overall survival (OS) was a key secondary endpoint (final analysis prespecified ≥ 60 months' follow-up). Patients were randomized to Rd continuous (n = 535), Rd18 (n = 541), or MPT (n = 547). At a median follow-up of 67 months, PFS was significantly longer with Rd continuous vs MPT (HR, 0.69; 95% CI, 0.59-0.79; P < .00001) and was similarly extended vs Rd18. Median OS was 10 months longer with Rd continuous vs MPT (59.1 vs 49.1 months; HR, 0.78; 95% CI, 0.67-0.92; P = .0023), and similar with Rd18 (62.3 months). In patients achieving complete or very good partial responses, Rd continuous had a ≈ 30-month-longer median time to next treatment vs Rd18 (69.5 vs 39.9 months). Over half of all patients who received second-line treatment were given a bortezomib-based therapy. Second-line outcomes were improved in patients receiving bortezomib after Rd continuous and Rd18 vs after MPT. No new safety concerns, including risk for secondary malignancies, were observed. Treatment with Rd continuous significantly improved survival outcomes vs MPT, supporting Rd continuous as a standard of care for patients with transplant-ineligible NDMM. Study registration is at Clinicaltrials.gov (NCT00689936) and EudraCT (2007-004823-39). |
| نوع الوثيقة: | article in journal/newspaper |
| وصف الملف: | ELETTRONICO |
| اللغة: | English |
| العلاقة: | info:eu-repo/semantics/altIdentifier/pmid/29150421; info:eu-repo/semantics/altIdentifier/wos/WOS:000423449900007; volume:131; issue:3; firstpage:301; lastpage:310; numberofpages:10; journal:BLOOD; http://hdl.handle.net/11585/614581Test; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-85040837714; http://www.bloodjournal.org/content/131/3/301?sso-checked=trueTest |
| DOI: | 10.1182/blood-2017-07-795047 |
| الإتاحة: | https://doi.org/10.1182/blood-2017-07-795047Test http://hdl.handle.net/11585/614581Test http://www.bloodjournal.org/content/131/3/301?sso-checked=trueTest |
| رقم الانضمام: | edsbas.60498923 |
| قاعدة البيانات: | BASE |
| DOI: | 10.1182/blood-2017-07-795047 |
|---|